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Abstract
Background: Up to 12% of beryllium-exposed American workers would test positive on beryllium lymphocyte
proliferation test (BeLPT) screening, but the implications of sensitization remain uncertain.
Methods: Seventy two current and former employees of a beryllium manufacturer, including 22 with pathologic
changes of chronic beryllium disease (CBD), and 50 without, with a confirmed positive test were followed-up for
7.4 +/-3.1 years.
Results: Beyond predicted effects of aging, flow rates and lung volumes changed little from baseline, while DLCO
dropped 17.4% of predicted on average. Despite this group decline, only 8 subjects (11.1%) demonstrated
physiologic or radiologic abnormalities typical of CBD. Other than baseline status, no clinical or laboratory feature
distinguished those who clinically manifested CBD at follow-up from those who did not.
Conclusions: The clinical outlook remains favorable for beryllium-sensitized individuals over the first 5-12 years.
However, declines in DLCO may presage further and more serious clinical manifestations in the future. These
conclusions are tempered by the possibility of selection bias and other study limitations.
Background
The beryllium lymphocyte proliferation test (BeLPT),
originally developed as a diagnostic tool for chronic ber-
yllium disease (CBD) [1,2], came into widespread use in
the 1990s as a surveillance test among asymptomatic,
clinically healthy, beryllium exposed workers [3-8]. Since
empiric evidence for screening efficacy has been lacking,
the choice was based on cross-sectional observations
[4-6] and anecdotal reports of progression to CBD in
BeLPT-positive workers initially free of clinical manifes-
tations [9]. It has been the working presumption that
some, or all of those sensitized to beryllium would
develop CBD in the future [3,10-12]. Rates of confirmed
positive tests varied among populations tested, ranging
from 2-12% [3,4,6-8,13,14]. Given the recent estimate of
as many as 134,000 workers currently exposed to beryl-
lium in the U.S. [15], and the likelihood that many more
were exposed in the past, these data and inferences
together would suggest a large potential burden of CBD
if more than a small percentage developed clinical mani-
festations. Since the disease as classically described is
highly morbid and carries a high mortality rate [16,17],
screening has generated a challenging set of issues con-
fronting clinicians who may care for identified “posi-
tives,” as well as questions regarding the efficacy of
screening.
D e s p i t ew i d ea p p l i c a t i o no ft h et e s ti ni n d u s t r ya n d
research studies, however, longitudinal observations to
document and quantify the natural history after initial
sensitization, or to identify factors that might confer
better or worse clinical trajectories, remain scant. Only
one such study has been published to date [18]. In this,
Newman and colleagues reported results of clinical and
pathologic re-evaluation on a series of 55 BeLPT-posi-
tive volunteers initially free of granulomas or compar-
able inflammatory changes in the lung based on BAL
and biopsy. Almost one-third subsequently developed
evidence of lung pathology compatible with CBD, after
an average follow-up of 4.8 years. The authors inter-
preted this as evidence supporting the presumption that
a high fraction of BeLPT-positive subjects will eventually
develop CBD, although their clinical data demonstrated
that few of their patients had clinical findings typical of
CBD, and only one was on treatment with systemic cor-
ticosteroids [19].
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knowledge about long term outcome after a confirmed
positive BeLPT test during routine surveillance of
exposed workers, including both those with and without
evidence of CBD on bronchoscopy and/or bronchoal-
veolar lavage at the time of initial surveillance. We
offered follow-up X-rays, lung function tests, physical
exams, questionnaires and repeat BeLPT testing to all
former and present employees of a single large beryllium
company identified as being BeLPT-positive during
workplace surveys conducted between 1992 and 2001.
Based on the results we have documented physiologic
course and estimated the rate of clinically apparent CBD
at follow-up, and determined risk factors, if any, for that
adverse outcome.
Methods
Study Population
The cohort comprised both former and current workers
at plants in Elmore, Ohio, Reading, Pennsylvania and
Tucson, Arizona who were positive on the BeLPT sur-
veillance test between 1992 and 2001 during employ-
ment, and had at least one confirmatory test. The parent
company provided contact information for 185 employees
initially identified. Three respondents were subsequently
deemed ineligible because of diagnoses made clinically
before surveillance testing and excluded. The resulting
group yielded the same population described by Donovan
et al except for the inclusion in our recruitment group of
5 additional BeLPT positive and confirmed subjects iden-
tified at Tucson after 2000, and the exclusion of the
Delta plant positives included in their paper but whose
numbers we considered too few to follow-up for practical
reasons[20]. An invitation to participate was mailed to
the last known address. Searches were made for subjects
whose initial letter was returned as undeliverable.
Plant medical records of consented subjects were
abstracted, as were records of the independent examina-
tions for CBD that had been recommended for all con-
firmed positives and completed by most at the time of
initial screening. That “baseline” exam included
bronchoscopy with bronchoalveolar lavage (differential
cell counts and BeLPT), and biopsy. Baseline lung func-
tion values were inferred from the studies obtained at
the specialty exam. In addition, summary demographic
data and baseline lung function were provided on non-
participants to address selection bias.
Subjects who agreed to participate were invited for
new “follow-up” examinations. Clinics near plant sites
were contracted to perform a standardized physical
examination, obtain a postero-anterior and lateral chest
X-ray, administer a questionnaire, draw and send blood
to two labs for BeLPT, and conduct pulmonary spirome-
try, total lung capacity and diffusion studies.
The protocol was approved by the Human Investiga-
tion Committee of the Yale University School of
Medicine.
BeLPT test
A blood sample was obtained and split, with one each
subsequently sent to National Jewish Medical and
Research Center (NJMRC; Denver, CO) and Specialty
Laboratories, (La Jolla, CA). Assays were performed as
previously published [3](Kreiss et al.1989).
Pulmonary Physiologic Assessment
Clinics differed in their equipment, but each followed
ATS quality guidelines [21,22]. Knudson predicted
norms were used for lung volumes and flow rates [23].
The predicted values of Crapo and Morris were used for
DLCO assessment [24]. To investigate possible effects of
inter-laboratory differences, serial lung function studies
obtained at the Ohio plant medical department were
abstracted on the subset of workers active at the plant
between 1994 and 2001 when DLCO testing was discon-
tinued on a routine basis.
Chest Radiographs
An experienced chest radiologist (A.M.C., a NIOSH-cer-
tified B reader) interpreted all chest radiographs–includ-
ing baseline, follow-up and interval films where
available–side-by-side, unblinded to film date. A chest
x-ray consistent with CBD was defined as having small
rounded opacities of profusion grade ≥1/0 based on the
ILO classification system, and/or mediastinal or hilar
lymphadenopathy [17,25].
Health and Exposure Survey
A specially developed questionnaire assessed post-
screening employment, medical history, history of atopy
and smoking status and incorporated a modified version
of the standardized American Thoracic Society respira-
tory questionnaire for cough, phlegm, wheeze, and
breathlessness. Exposure to beryllium was assessed by
years worked, time since leaving the exposure, and
whether or not they remained employed in a workplace
using beryllium after initially screening positive.
Classification of Baseline Status
Subjects had been classified as beryllium sensitized
(BeS) if they had two or more abnormal BeLPT tests
and no evidence of granulomas and/or mononuclear cell
infiltrates on trans-bronchial lung biopsy at the time of
baseline evaluation [17,25]. Subjects were classified as
having surveillance detected CBD if they had, in addi-
tion, granulomas and/or mononuclear cell infiltrates in
lung tissue, or had lymphocytosis (>20%) and positive
BeLPT on BAL. The small number of sensitized workers
who initially refused bronchoscopy but had no clinical
abnormalities were also classified as BeS.
Criteria for Clinical Abnormality at Follow-up
We defined a subject as having a clinical abnormality con-
sistent with CBD if the manifested one or more of the
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changes typical of CBD; 2) Total lung capacity and/or
FVC <80% predicted; 3) DLCO <80% predicted absent
COPD, or 4) Treatment with oral steroids for CBD by a
physician.
Note: Subjects were considered to have COPD if:
1) they were former or current smokers, and 2) met
GOLD criteria for Stage II (FEV1/FVC less than 70%
and FEV1 < 80% predicted), and 3) had evidence of air-
trapping or bullous disease on chest X-ray and/or total
lung capacity >100% predicted.
Statistical Analysis
Chi-square and Student t-tests were used to compare the
recruited subjects with those who did not respond or
elected not to participate. Linear regression techniques
and analysis of variance were used to assess lung function
changes. Development of clinically manifest CBD was
estimated for the entire group, and separately for BeS
and CBD subgroups, using the Kaplan-Meier survivor
functions. Candidate predictors for clinical signs included:
duration of follow-up, demographics, work history, atopy,
smoking history, baseline functional status and follow-up
BeLPT results (i.e., persistent beryllium sensitivity). Con-
tinuous variables were compared using Student’st - t e s t .
Categorical characteristics were compared between sub-
groups using Fisher’s exact test. Differences for all com-
parisons were considered significant when p < 0.05 in a
2-sided test. Analysis was performed using Stata version
8.0 (Stata Corporation, College Station, TX, USA).
Results
Recruitment and Baseline Characteristics
Of the 182 eligible subjects with confirmed positive
BeLPT tests at one of the waves of workplace screening
between 1992 and 2001, 72 (40%) agreed to participate
overall. This represented a 54% response at the largest
(Ohio) facility, but <25% at the two smaller sites. Sub-
jects with CBD diagnosed at baseline were significantly
less likely to participate, p < .02. Recruitment is depicted
in Figure 1: Cohort recruitment schema.
Table 1 shows the baseline characteristics of the parti-
cipants at the time of their initial identification as
Figure 1 Cohort Recruitment Schema.
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portion of females and still-active at the plant was the
same, but whites were more likely than others to partici-
pate, p < .01. Mean age among those who participated
was higher (4.4 years on average), but adjusted for age,
baseline lung function was almost identical on every
parameter including DLCO (data not shown).
Subjects were further stratified based on the outcome
of their initial complete evaluation as “Beryllium Sensi-
tized” (BeS), implying no pathologic evidence of CBD
was found on biopsy and BAL (N = 44) or the test was
not performed at baseline (N = 6); or CBD (N = 22). As
can be seen, the groups did not differ appreciably on
demographic characteristics, length of work experience,
smoking, allergy history or lung function, although those
with CBD had lower FVC. Not demonstrated, ever-smo-
kers in each subgroup had significantly lower FEV1 and
FEV1/FVC levels than non-smokers; current smokers
had lower DLCOs. Twelve smokers had moderate or
severe COPD, 10 (20%) of the BeS subjects and 2 (9%)
with CBD, a non-significant difference in rate, p = 0.32.
Table 1 shows the baseline characteristics of the two
groups with and without these subjects included.
Clinical Outcome at Follow-Up
Table 2 shows the changes in lung function from base-
line examination to follow-up. In 8 subjects the total
lung capacity and/or DLCO could not be calculated
because of patient cooperation or technical problems.
Over an average of 7.4 +/- 3.1 years there was little
change in the mean % of predicted for FEV1 (-1.8%),
FVC (- 1.8%), or FEV1/FVC (+ 0.04%), although ever-
smokers lost function on each parameter significantly
faster than non-smokers (data not shown). The change
in TLC % predicted was larger, but similar across the
Table 1 Baseline demographic and exposure profile of participants initially classified as Chronic Beryllium Disease
(CBD) and Beryllium Sensitization (BeS), with and without those with COPD
BeS COPD in (n = 50) CBD COPD in (n = 22) P value BeS COPD out (n = 40) CBD COPD out (n = 20) P value
Age in years (s.d.) 44.2 (11.1) 47.8 (10.5) 0.20 42.6 (11.2) 46.7 (10.2) 0.17
Sex (% male) 78 77 0.95 73 80 0.53
Race (% white) 94 100 0.71 93 100 0.66
Smoking Status
Non-smoker % 42 36 50 40
Ex smoker % 20 36 0.32 18 40 0.16
Current smoker % 38 27 33 20
Mean length from hire
date to baseline
evaluation in years
(s.d)
12.4 (11.1) 13.7 (7.0) 0.60 11.6 (10.1) 14.3 (7.0) 0.28
Period of beryllium
exposure in years
(s.d)
15.6 (11.8) 18.0 (8.4) 0.41 15.1 (11.7) 18.7 (8.5) 0.22
Time from baseline to
follow-up evaluation
(s.d)
7.1 (3.0) 8.1 (3.4) 0.20 7.0 (3.0) 8.5 (3.4) 0.09
History of hay fever,
asthma or eczema
(% positive)
48 50 0.96 50 45 0.72
Pulmonary Function
Tests
FEV1 mean %
predicted (s.d.)
89.3 (14.5) 86.2 (16.7) 0.43 92.6 (12.7) 89.1 (14.3) 0.33
FVC mean % predicted
(s.d.)
96.1 (14.8) 88.8 (11.7) 0.04 97.9 (14.3) 89.6 (11.5) 0.03
FEV1/FVC mean %
predicted (s.d)
92.8 (10.3) 95.0 (12.0) 0.44 95.6 (8.1) 97.0 (8.1) 0.52
DLCO mean %
predicted (s.d.)
101.3 (16.1) 99.9 (23) 0.77 103.6 (14.2) 104.0 (20.1) 0.94
TLC mean %
(predicted) (s.d.)
98.6 (14.6) 94.5 (14.5) 0.35 98.6 (14.3) 91.5 (12.0) 0.10
Clinical evidence of
COPD N (%)
10 (20) 2 (9.1) 0.32
* 3 subjects initially eligible were excluded after record review as they did not meet study criteria
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COPD. In contrast, the final-initial difference in DLCO
% predicted was significant and large: - 17.3%. This
decline was similar across all groups, BeS and CBD,
with and without COPD. Analysis of variance showed
that declines were equivalent at all three sites. There
was no significant relationship between change in DLCO
and baseline status, BeLPT at follow-up, duration of ber-
yllium exposure or smoking, but these was a significant
positive correlation (p < .02) between loss and length of
follow-up as illustrated in Figure 2.
B e Ss u b j e c t sl o s ta tar a t eo f1 . 4 %p e ry e a r ,w h i l e
those with lung involvement at baseline lost an average
of 2.7% annually, but this difference was not significant.
Neither percent lymphocytes on initial BAL, nor biopsy
findings, added greater predictive value regarding DLCO
decline. Notably, the 19 subjects followed continuously
at the plant lung function laboratory between 1994 and
Table 2 Mean percent predicted values for physiologic parameters at baseline and at follow-up for each clinical
subgroup (p < .05 for differe ce in italics)
Pulmonary Function Tests BeS COPD In BeS COPD out BeS COPD CBD COPD In CBD
COPD out
CBD COPD
N5 0 4 0 1 0 2 2 2 0 2
FEV1 % Before 89.3 92.6 76.2 86.2 89.1 57.9
After 88.2 91.1 77.0 82.7 86.2 48.4
Difference 1.1 1.6 -0.8 3.5 2.9 9.5
FVC % Before 96.1 97.9 89.1 88.8 89.6 80.9
After 94.4 94.6 93.5 87.0 88.9 67.5
Difference 1.8 3.3 -4.4 1.9 0.7 13.5
FEV1/FVC % Before 92.8 95.6 81.8 95.0 97.0 74.5
After 92.9 95.6 82.0 95.0 98.0 64.9
Difference -0.0 -0.0 -0.2 -0.0 -1.0 9.6
DLCO mean %* Before 101.3 103.6 92.2 99.9 104.0 59.4
After 85.7 87.8 75.5 79.6 83.4 41.8
Difference 16.0 15.8 16.7 20.3 20.6 17.6
TLC mean %* Before 98.6 98.6 98.7 94.5 91.5 125.1
After 94.5 93.5 98.2 86.4 85.6 94.3
Difference 4.2 5.1 0.5 8.1 5.9 30.8
* Data missing for 8 subjects
Figure 2 Difference in DLCO percent predicted (Crapo) between baseline and follow-up visits versus time between examinations.
Linear regression lines are depicted for the entire group and each of the subgroups based on baseline lung evaluation.
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time (+/- SD 14.5%, range 44% loss to 15% gain).
Because of concern about drawing strong inferences
based on DLCO changes alone, since pre- and post-
values were obtained in different laboratories for all
subjects and compared only at two points in time, we
evaluated the cases also from a clinical perspective, clas-
sifying each separately using the above stated criteria.
This seemed as well another way of managing the possi-
ble confounding effects of COPD, which was prevalent
among study subjects as noted. By our criteria,
8 (11.1%) of the 72 subjects demonstrated one or more
clinical manifestations of CBD based on typical X-ray
changes (N = 2), a pattern of restrictive/interstitial lung
dysfunction (N = 4), abnormal DLCO (N = 6), or some
combination thereof. In only two was a low DLCO the
sole criterion for inclusion, so this result is, in part at
least, independent of the observation regarding DLCO
loss. Results of follow-up examinations for these 8 indi-
viduals are summarized in Table 3. As shown, patient 7
had no clear clinical manifestation of CBD, but had
been started on oral steroids for presumed CBD by his
physician; he was unable to complete the TLC and
DLCO testing at follow-up.
Table 4 depicts the follow-up data for the entire group,
stratified by baseline category. As can be appreciated,
t h e r ew e r ed i f f e r e n c e si nt h ef a t eo ft h et w og r o u p s .
About 3/4 of those with CBD at baseline remained posi-
tive on the BeLPT in one or both labs, compared to 42%
of the those with BeS at baseline (p = 0.035). More strik-
ingly, while 7 of 22 with CBD demonstrated one or more
clinical manifestations of CBD (31.8%) at follow-up, only
1 of the 50 (2%) with BeS at baseline met the criteria, a
significant difference, p < .001. Using Kaplan-Meier survi-
vor analysis of the two groups from the time of initial
positive screening to the time of follow-up, this difference
was also highly significant, p < .002.
Predictors of Clinical Disease at Follow-up
The strongest predictor of clinical manifestations of
CBD at follow-up was the presence of CBD related
pathology in the lung at the time of initial evaluation.
Specific biopsy changes made no difference, nor did the
percent lymphocytes or granulocytes on initial BAL.
Among those with initial changes, 31.8% had clinical
abnormalities typical of CBD at follow-up, raising the
question whether any characteristic(s) determined at
baseline, or subsequently, might be associated with risk.
Demographics, baseline clinical status, allergy history,
smoking history, prior beryllium exposure (measured
crudely as years worked in the plant), continuation of
work around beryllium, results of the BAL, and persis-
tent blood BeLPT reactivity were all considered. As can
be seen in Table 5, none appear strongly associated,
although the clinical CBD cases did have, on average,
lower FVC and FEV1 at the outset than those who did
not manifest such changes.
DLCO levels, which proved most often abnormal at
follow-up, were almost identical between the groups at
the outset. By way of caution, however, neither quantita-
tive beryllium exposure, nor HLA genotype, each con-
sidered ap r i o r irelevant as predictors of long-term
outcome, was available for this comparison. Moreover,
the number of CBD cases was too small to exclude
some beneficial effects, for example, from leaving beryl-
lium exposure or quitting smoking.
BeLPT Results at Follow-Up
Sixty-three of the subjects had repeat BeLPT testing on
a split sample at two separate labs–National Jewish and
Specialty Lab. Five subjects refused to be tested, and in
4 others, a satisfactory test was unable to be performed
by one lab or the other. Only 15, (24.1%) were positive
at both labs on follow-up while 19 were positive in one
lab but negative in the other. Thirty-three subjects were
negative. Overall agreement between the labs, as shown
on Table 6, was almost 68%, with a Kappa of 0.43, sig-
nificantly different from “random,” p < .0008.
Discussion
To our knowledge this is the first reported clinical fol-
low-up of a population-based groups of subjects identi-
fied as being blood BeLPT positive on routine
workplace surveillance. Overall, the findings are mixed.
On the one hand, this study shows that the fraction of
subjects who have developed objective clinical manifes-
tations typical of CBD, at 11.1%, is low. Moreover, from
a clinical perspective the severity in each of the 8 cases
observed is mild to moderate; only one of the patients
has been treated with systemic corticosteroids by their
physician, although each is under the care of a pulmo-
nologist. For the subset of subjects who proved negative
on initial full lung evaluation, the results appear even
more favorable; only 1 of 50 meets our criteria for clini-
cal CBD. Half of these subjects, unlike most who had
CBD at the outset, have lost their BeLPT positivity.
On the other hand, while few subjects met criteria for
CBD, there appears to be a drop in % predicted DLCO
in many more subjects, including those without estab-
lished lung involvement at baseline. Although not asso-
ciated with group changes in lung volumes or flow
rates, three lines of evidence suggest these decrements
are not merely an artifact of the fact that pre and post
testing was conducted in different labs, nor that only
two data points were used to calculate change. First, the
average drop of 17.4% was almost identical for subjects
at each testing site, which speaks against lab variation as
the major explanation. Second, the significant trend
with time since initial BeLPT positivity (Figure 2)–but
not age or duration of exposure–would seem most
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Page 7 of 10consistent with progressive, albeit slow loss. As noted,
those with CBD at baseline appear to be losing faster
than those without, on average. Third, among the subset
of still active workers between 1994 and 2001 continu-
ously tested at the plant, losses averaged well over 1%
decline from predicted per year.
Unfortunately, we were unable to delineate any factor
or factors other than baseline pathology that predicted
rate of loss or development of clinical signs. However,
two of the most important potential factors, smoking
cessation and cessation of all beryllium exposure, would
only have been noticeable with an overwhelming effect
since the population size is too small. Two other factors
considered relevant, extent of prior exposure to beryl-
lium and HLA-DP polymorphism [10,11], could not yet
be evaluated because we have not linked our results
with sources for these data.
Beyond these, there are some other important limita-
tions of our study. Most obviously, although we recruited
54% of the eligible cohort members at the largest site,
recruitment overall was less than hoped (72/182 identi-
fied) so we cannot be certain that no selection bias was
introduced. In theory, subjects with better or worse out-
comes could have selectively chosen to either participate
or not, although except for the lesser participation of
younger workers and non-whites, baseline characteristics
were very similar between those who did and did not
come. Notwithstanding our efforts to communicate the
independence of the investigators from the employer-
sponsor, all subjects were aware of our funding source.
This may have influenced some subjects’ decisions intro-
ducing bias in either direction in theory,
Another important limitation of this study was the reli-
ance on clinical observations to establish key end-points of
the study, namely the paired chest X-rays and paired lung
function tests–done in different labs. Most problematic
were the lung function studies. While all attempts were
made to follow ATS procedures [21,22] at follow-up
exams, we were unable to verify the procedures where
baseline respiratory examinations were conducted, though
most were in the laboratories of university medical cen-
ters. Furthermore, the high prevalence of COPD in the
study population by our definition (N = 12, 16.7%), whose
changes over the follow-up period could potentially con-
found group interpretation of the physiologic data, dic-
tated that we use a clinical end-point for the study rather
than rely strictly on group physiologic observations. In
point of fact, however, each of the cases were, on review,
easily classifiable despite the fact that diminished DLCO
was the most prevalent reason for classification as CBD
(present in 6 subjects and the only basis for classification
in 2, see Table 3). Still, some physiologic contribution by
CBD in the 12 patients with COPD cannot be ruled out.
This possibility underscores a final limitation, namely that
we did not, like Newman [18](Newman et al, 2005), repeat
the biologic assessment for pathologic or BAL changes of
Table 4 Follow up Clinical Examination Results
Questionnaire variables BeS COPD in
(n = 50)
CBD COPD in
(n = 22)
P value BeS COPD out
(n = 40)
CBD COPD
out
(n = 20)
P value
History of hay fever, asthma or eczyma
(% positive)
48 50 0.96 50 45 0.72
Steroid use (Inhaled or Oral) % 4 32 0.001 5 25 0.023
Smoking Status
Nonsmoker % 42 36 48 40
Ex smoker % 42 55 0.56 38 55 0.32
Current smoker % 16 9 15 5
% still working at beryllium-using facility 36 23 0.27 40 20 0.12
Current BeLPT test results %*
(+/+) 17 43 0.025 21 42 0.03
(+/-) 26 33 21 37
(-/-) 57 24 58 21
Clinical CBD N (%) 1(2.0%) 7(31.8%) 0.001 1(2.5) 7(35.0) 0
Pulmonary Function Tests (% predicted)
FEV1 (s.d) 88.2(17.4) 82.7(21.3) 0.25 91.1(13.0) 86.2(16.7) 0.22
FVC (s.d.) 94.4 (18.5) 87.0(18.4) 0.12 94.6(14.0) 88.9 (15.7) 0.14
FEV1/FVC (s.d) 92.9 (10.2) 95.0 (14.1) 0.47 95.6(8.4) 98.0(9.6) 0.32
DLCO (s.d.) 85.4(20.8) 79.6(20.8) 0.30 87.8(15.9) 83.4(17.4) 0.36
TLC (s.d.) 94.5(19.1) 86.4(14.4) 0.05 93.5(14.6) 85.6(14.7) 0.07
*9 participants had either only 1 or no BeLPT test(4 had 1 test and 5 had no test result)
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Page 8 of 10CBD; some of those initially classified as BeS may have
evolved over time, and subsequently be, theoretically, at
greater risk for clinical disease.
Where does this new data leave us in the effort to con-
trol CBD? First, we have affirmed our earlier impression
that the BeLPT, despite its limitations [26,27] (Table 5),
detects subjects at some risk for clinical disease once
confirmed by a second positive test. In fact, some of
those detected at screening already had evidence of clini-
cally manifest disease at first recognition (cf patients 2
a n d5 ,T a b l e3 ) ,s u g g e s t i n gt h a tt h eo f t e nu s e dt e r m
“sub-clinical CBD” m a yb el e s sp r e c i s ef o rd e s c r i b i n g
such patients than an alternative designation such as
“surveillance-detected CBD.” Whether BeLPT positivity
(confirmed) carries similar implications among indivi-
duals whose exposures may have been more limited is
uncertain, as our subjects were all workers in primary
beryllium-related occupations. Also uncertain is the bene-
fit of identifying at-risk individuals in the absence of any
action known to alter their clinical outcome.
When testing is performed, the optimal approach to
follow-up of confirmed BeLPT positives also remains
unresolved. Full pulmonary evaluation, with broncho-
scopy, biopsy, and BAL, may be justified given the sug-
gestion of a different prognosis for those with vs. those
without lung involvement, but this benefit remains
unproved. Although we continue to support removal
from continued occupational beryllium exposure based
on a precautionary point of view, we would be hard
pressed to take a more rigid position based on our
results in a case where an individual chose to remain in
exposed work, as many of our subjects in this study did,
despite advice and a generous economic package, with-
out obviously greater risk than those who chose to
leave. Hopefully, given the continued interest in CBD,
better scientific foundations for these clinical and public
health decisions will not be far off.
Table 5 Predictors of clinical disease among participants with CBD at baseline
Baseline Characteristics WITHOUT clinical CBD at follow-up
n=1 5
WITH clinical CBD at follow-up
n=7 *
P value
Age in years (s.d.) 45.6 (9.27) 52.6 (12.0) 0.15
Race (% white) 93 100 0.48
Sex (%male) 73 86 0.52
History of hay fever, asthma or eczema % 47 57 0.65
Mean length from hire date to baseline evaluation,
in years (s.d)
13.7 (5.9) 13.9 (9.4) 0.95
Period of beryllium exposure, in years (s.d) 18.6 (8.1) 16.6 (9.7) 0.61
Time from baseline to follow-up evaluation (s.d) 8.3 (2.9) 7.7 (4.4) 0.70
Baseline PFTs (% predicted (s.d.))
FEV1 87.5 (16.3) 83.4 (18.3) 0.60
FVC 91.2 (12.2) 83.7 (9.3) 0.17
FEV1/FVC 95.9 (13.1) 92.9 (9.9) 0.60
DLCO 98.1 (23.9) 104.3 (22.0) 0.59
TLC 95.8 (17.2) 92.4 (9.0) 0.64
Follow-up Characteristics
Smoking Status
Nonsmoker % 40 29
Ex smoker % 47 71 0.44
Current smoker % 13 0
% still working at beryllium facility 27 14 0.52
BeLPT results *
(+/+) 40 50
(+/-) 33 33 0.89
(-/-) 27 17
* result for 1 person was missing
Table 6 Comparison at follow-up of split sample blood
for BeLPT
Lab 1
Lab 2 + ve -ve
+v e 15 12
-v e 72 9
K = 0.43, Agreement = 68.06%, P = 0.0008
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Page 9 of 10Conclusions
The clinical outlook remains favorable for beryllium-
sensitized individuals over the first 5-12 years. However,
declines in DLCO may presage further and more serious
clinical manifestations in the future. These conclusions
are tempered by the possibility of selection bias and
other study limitations.
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